2025-06-10-花旗集团-梅鲁斯（MRUS）_Merus（MRUS.O）2025年第一季度模型更新_13页_604kb

Merus (MRUS.O) 1Q25 Model Update Summary

Core Content Overview

Merus (MRUS.O) is a commercial oncology company that develops innovative antibody-based therapeutics using its Multiclonics platform, which enables the creation of bispecific and trispecific antibodies for the treatment of solid tumors. The company recently received approval for Bizengri, a bispecific antibody targeting HER2-/HER3-positive pancreatic adenocarcinoma and non-small cell lung cancer (NSCLC) with NRG1 gene fusions. The company is also advancing petosemtamab (MCL-158) in two Phase 3 trials for the treatment of first-line (1L) and second-line (2L) metastatic head and neck squamous cell carcinoma (r/m HNSCC), and MCLA-129 (EGFR x c-MET) in early-stage trials for lung and other solid tumors.

Main Points and Key Information

Investment Rating and Target Price

• Investment Rating: Buy / High Risk
• Current Price (09 Jun 25 16:00): US$54.91
• Target Price (1Q25 Update): US$102.00
• Expected Share Price Return: 85.8%
• Expected Total Return: 85.8%
• Market Cap: US$4,087M

Financial Highlights (2023–2027E)

• Sales Revenue:
  • 2023: €44M
  • 2024: €36M
  • 2025E: €36M
  • 2026E: €16M
  • 2027E: €78M
• Gross Profit:
  • 2025E: €36M
  • 2026E: €13M
  • 2027E: €66M
• Gross Margin:
  • 2025E: 99.1%
  • 2026E: 85.0%
  • 2027E: 85.0%
• Pre-Tax Profit:
  • 2025E: -€448M
  • 2027E: -€74M
• Net Margin (2027E): -95.4%
• Core NPAT (2027E): -€72M
• EBIT (Adj) (2027E): -€66M
• EBITDA (Adj) (2025E): -€430M
• EBITDA Margin (Adj) (2027E): -85.0%

Valuation Metrics

• PE (x):
  • 2025E: -7.9
  • 2027E: -50.0
• PB (x):
  • 2025E: 6.1
  • 2027E: 25.4
• EV/EBITDA (x):
  • 2025E: -6.7
  • 2027E: -53.1
• FCF Yield (2025E): -11.7%
• 12-Month Target Price: US$102.00
• WACC Used: 12.5%
• Terminal Growth Rate (post 2035): -15% (to highlight platform value)

Key Programs and Positivity Assumptions

• Bizengri:
  • 95% PoS for other solid tumors in the US and EU
  • Risk-adjusted WW peak royalties: ~€65M by 2035
• Petosemtamab:
  • 80% PoS for 1L and 2L treatment in the US and EU
  • Risk-adjusted WW peak sales: ~€3.3B by 2035
• MCLA-129:
  • 30% PoS in the US and EU
  • Risk-adjusted US peak sales: ~€555M
  • Risk-adjusted EU peak royalties: ~€67M

Risks

• High risk rating due to biotech stock volatility and uncertainty in clinical trials.
• Key risks include:
  • Commercial uptake for NRG1+ NSCLC and PDAC not meeting expectations.
  • Competing therapies showing superior safety or efficacy.
  • Future pivotal data for petosemtamab not confirming earlier positive findings.

Catalyst Watch and Short-Term View

• Direction: Upside
• Duration: Within 90 Days
• Recent Catalysts:
  • Positive Phase 2 data for petosemtamab presented at ASCO.
  • Potential for initial data from Phase 2 trials of petosemtamab in metastatic colorectal cancer (mCRC) in 2H25.

Summary of Investment Thesis

Merus is rated Buy / High Risk, with a 12-month target price of US$102.00, representing an 85.8% expected share price return. The updated model reflects higher-than-expected collaboration revenue and royalty income from initial sales of Bizengri, which has further de-risked the company's platform. The firm's innovative Multiclonics platform offers potential advantages over competitors in terms of screening-rate, stability, cytotoxicity, and manufacturability.

While financial performance remains negative, the company's pipeline, particularly petosemtamab, shows strong potential. The analysis highlights the importance of clinical trial outcomes and market adoption of its products. The valuation model is based on DCF analysis and platform value considerations, with a negative terminal growth rate to reflect the current risk profile.

Analyst and Disclosure Notes

• Analyst: Yigal Nochomovitz, Ph.D.
• Citi Research has a potential conflict of interest due to its investment banking relationship with Merus.
• The analyst's compensation is based on activities and services intended to benefit the Firm's clients, including corporate access events.
• Citi Research is a liquidity provider and may trade in the company's securities, which could impact recommendations.

Appendix Notes

• Analyst Certification: All analysts certify the views expressed in the report.
• Important Disclosures:
  • Citi Research is a division of Citigroup Global Markets Inc.
  • Citi owns a position of 1 million USD or more in Merus debt securities.
  • Citi has been an investment banking client of Merus within the past 12 months.
• Catalyst Watch/Short Term Views:
  • The rating system includes Upside/Downside calls for short-term share price movements.
  • Catalyst Watch is published when analyst confidence is high, and STV when it is moderate.
  • The Catalyst Watch is linked to specific near-term events, such as clinical data releases.

Conclusion

Merus presents a high-risk, high-reward investment opportunity due to its innovative platform and promising pipeline. The updated model reflects positive momentum from recent clinical data, particularly from petosemtamab, and potential royalty income from Bizengri. Despite financial losses, the company's platform value and market potential are key drivers of the Buy recommendation. Investors should carefully consider the risks associated with clinical trials and market adoption before making investment decisions.